Article

Ongoing botulinum injections' efficacy in question

The treatment benefit of intradetrusor onabotulinumtoxinA (Botox) for urinary incontinence due to neurogenic detrusor overactivity may decline after patients have received multiple repeat injections, findings from a study by Taiwanese urologists suggest.

Related Videos
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
1 expert is featured in this series.
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
2 experts are featured in this series.
2 experts are featured in this series.
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Related Content
Published data support safety, efficacy of vaginal insert for SUI
May 14th 2025

Published data support safety, efficacy of vaginal insert for SUI

Hannah Clarke
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Long-term data point to durable efficacy of Optilume for urethral strictures
May 13th 2025

Long-term data point to durable efficacy of Optilume for urethral strictures

Hannah Clarke
The freedom from re-intervention rate was 71%.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
National Women’s Health Week: Celebrating women shaping the future of urology
May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke
"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke
The phase 3 RC48-C016 trial met its primary end points.
© 2025 MJH Life Sciences

All rights reserved.